Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin (Q37468406)

20 August 2017

Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin (English)

1 reference

20 August 2017

0 references

Daniel A Tatosian

1

1 reference

20 August 2017

Ying Guo

2

1 reference

20 August 2017

Andrea K Schaeffer

3

1 reference

20 August 2017

Natalia Gaibu

4

1 reference

20 August 2017

Serghei Popa

5

1 reference

20 August 2017

Aubrey Stoch

6

1 reference

20 August 2017

Ronald B Langdon

7

1 reference

20 August 2017

Eunkyung A Kauh

8

1 reference

20 August 2017

26 October 2013

1 reference

20 August 2017

1 reference

20 August 2017

4

1 reference

20 August 2017

2

1 reference

20 August 2017

431-442

1 reference

Creative Commons Attribution 2.0 Generic

20 August 2017

start time

26 October 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s13300-013-0045-8

0 references

cites work

Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3889317

Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3889317

Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3889317

Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3889317

The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3889317

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3889317

Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3889317

Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3889317

Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3889317

Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3889317

Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3889317

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3889317

Determination of sitagliptinin human plasma using protein precipitation and tandem mass spectrometry

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3889317

Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3889317

Discovery of potent and selective orally bioavailable beta-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3889317

Small sample inference for fixed effects from restricted maximum likelihood.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3889317

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

2 September 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-013-0045-8

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-013-0045-8

Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-013-0045-8

Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-013-0045-8

10.1007/S13300-013-0045-8

21 January 2018

Identifiers

DOI

1 reference

release_xu3g5bbabnfxhdlfgh7gdh34ai

20 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xu3g5bbabnfxhdlfgh7gdh34ai

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

20 August 2017

1 reference